Doctors Note Logo

Published on: 9/23/2026

Which COVID vaccine is best, and how do they compare?

No single COVID vaccine is universally "best," since the updated mRNA options (Pfizer-BioNTech Comirnaty and Moderna Spikevax) and the protein-based Novavax Nuvaxovid all offer strong protection against severe illness, hospitalization, and death. They differ in technology, age eligibility, dosing schedules, and typical side effects, with mRNA vaccines more often linked to short-lived fever, fatigue, and sore arm, and Novavax sometimes chosen by people who prefer a traditional protein-based approach or had reactions to mRNA doses. The right choice depends on your age, pregnancy status, immune condition, allergy history, prior vaccine reactions, and what is available locally, so there are several important factors to consider before deciding, as explained below.

If you are weighing your options because you already feel unwell, run down, or unsure whether your symptoms are COVID, a cold, flu, or a vaccine reaction, clarity matters more than guesswork. Take a free, instant, online symptom check to understand what may be driving how you feel and get guidance on the smartest next steps, including whether to test, rest, or contact a clinician before your next dose.

Last reviewed for medical accuracy: 09/23/2025

answer background

Explanation

Which COVID vaccine is best, and how do they compare?

Choosing “which COVID vaccine is best” depends on factors like your age, health status and local availability. All approved vaccines provide strong protection against severe disease and hospitalization. Here’s a clear comparison to help you understand your options.

Overview of available COVID-19 vaccines

  • mRNA vaccines
    • Pfizer-BioNTech (Comirnaty)
    • Moderna (Spikevax)
  • Viral vector vaccines
    • Johnson & Johnson (Janssen)
    • AstraZeneca (Vaxzevria) – approved in many countries but not in the U.S.
  • Protein subunit vaccine
    • Novavax (Nuvaxovid)

Each platform trains your immune system in a different way, but all authorized vaccines meet high standards for safety and effectiveness.

Efficacy and real-world effectiveness

Vaccine clinical trials measure “efficacy” under ideal conditions, while real-world studies show “effectiveness.” Here’s how the main vaccines compare:

  • Pfizer-BioNTech
    • Trial efficacy against symptomatic infection: ~95%
    • Real-world effectiveness against hospitalization: >90%
  • Moderna
    • Trial efficacy against symptomatic infection: ~94%
    • Real-world effectiveness against hospitalization: >90%
  • Johnson & Johnson
    • Trial efficacy against moderate-to-severe disease: ~66% globally
    • Effectiveness against hospitalization: ~85%
  • AstraZeneca
    • Trial efficacy against symptomatic infection: ~70% average (varies by dosing interval)
    • Effectiveness against hospitalization: ~90%
  • Novavax
    • Trial efficacy against symptomatic infection: ~90%
    • Data on hospitalization protection still emerging

All vaccines perform best against severe outcomes (ICU admission, death). Effectiveness against any infection can wane over time, especially with new variants—booster doses restore strong protection.

Safety and side effects

Common side effects usually occur within 24–48 hours and resolve quickly. They’re signs your immune system is responding.

  • Local reactions (injection-site pain, redness, swelling)
  • Systemic reactions (fatigue, headache, muscle aches, mild fever)
  • Rare events
    • Myocarditis/pericarditis: slightly increased risk in young males after mRNA vaccines, but mostly mild and treatable
    • Thrombosis with thrombocytopenia syndrome (TTS): very rare with Johnson & Johnson and AstraZeneca
    • Anaphylaxis: extremely rare; vaccination sites are equipped to manage it

Overall, the risk of serious side effects is far lower than the risk of severe COVID-19, especially for those with risk factors.

Dosing schedules and boosters

  • Pfizer-BioNTech
    • Primary series: 2 doses, 3–8 weeks apart
    • Booster: recommended 2 months after primary series for adults; timing may vary for younger ages
  • Moderna
    • Primary series: 2 doses, 4–8 weeks apart
    • Booster: recommended 2–6 months after primary series
  • Johnson & Johnson
    • Primary series: single dose
    • Booster: recommended at least 2 months after initial dose; a second booster may be advised for some groups
  • AstraZeneca
    • Primary series: 2 doses, 4–12 weeks apart
    • Booster: varies by country; often mRNA booster recommended
  • Novavax
    • Primary series: 2 doses, 3–4 weeks apart
    • Booster: under review

Boosters enhance protection against emerging variants and counter waning immunity.

Special considerations

  1. Age and health conditions
    • mRNA vaccines (Pfizer, Moderna) are preferred for most age groups due to strong protection and extensive safety data.
    • Johnson & Johnson may suit people who have difficulty returning for a second dose, but it has lower overall efficacy and a tiny risk of TTS.
    • Novavax is an option for those wary of mRNA or viral-vector platforms.
  2. Allergies
    • If you have a history of severe allergic reactions to a vaccine component (e.g., polyethylene glycol in mRNA vaccines), talk to an allergy specialist.
    • Alternatives (Johnson & Johnson, Novavax) may be available based on local approvals.
  3. Pregnancy and breastfeeding
    • mRNA vaccines have the most data and are generally recommended for pregnant and breastfeeding individuals.
  4. Immunocompromised status
    • A three-dose primary series of mRNA vaccine is often advised, followed by boosters.
  5. Vaccine availability
    • What’s “best” is also what’s accessible. All approved vaccines significantly reduce severe COVID-19.

Which COVID vaccine is best for you?

No single vaccine is “best” in every situation. Consider these factors:

  • How soon you can get your first dose and complete the series
  • Your age, health risks and allergy history
  • Whether you can return for a second dose or prefer a single-dose option
  • Local regulatory guidance and availability

Talk through these points with your healthcare provider. They’ll tailor advice to your personal health needs.

Monitoring symptoms and next steps

After vaccination—or if you develop COVID-like symptoms—it’s helpful to track how you feel. For a free, online symptom check, using the doctor approved Ubie Symptom Checker, click here: https://ubiehealth.com/ to get personalized guidance and know when to seek care.

When to seek medical attention

Always speak to a doctor if you experience:

  • Symptoms that worsen or persist beyond a few days
  • Difficulty breathing, chest pain, confusion, or blue lips
  • High fever not improving with home measures
  • Any sign of an allergic reaction (hives, swelling of face/lips/ throat, difficulty breathing)

These could indicate a life-threatening condition requiring urgent evaluation.

Take-home points

  • All authorized COVID-19 vaccines strongly protect against severe disease and death.
  • mRNA vaccines (Pfizer-BioNTech, Moderna) offer the highest efficacy in clinical trials and extensive real-world data.
  • Johnson & Johnson provides a single-dose option but has a slightly lower efficacy and very rare clotting risk.
  • Novavax may appeal to those looking for a non-mRNA, protein-based vaccine.
  • Choose the vaccine you can access promptly—early protection is vital.
  • Stay up to date with boosters to maintain immunity against new variants.
  • For personalized symptom guidance, use the doctor-approved Ubie Symptom Checker.
  • Always consult your healthcare provider with any serious or concerning symptoms.

Speak to a doctor about which COVID vaccine is best for you and for any health changes that could be life threatening or serious. Your healthcare team will help you make the safest, most effective choice.

(References)

  • * Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, Cortes FH, Grifoni A, Tarke A, Chang J, Escarrega EA, Kim C, Goodwin B, Bloom NI, Frazier A, Weiskopf D, Sette A, Crotty S. Humoral and cellular immune memory to four COVID-19 vaccines. Cell. 2022 Jul 7;185(14):2434-2451.e17. doi: 10.1016/j.cell.2022.05.022. Epub 2022 May 27. PMID: 35764089; PMCID: PMC9135677.

  • * Nuñez NG, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, Unger S, Blanco S, Konigheim B, Marín C, Onofrio L, Kienzler JC, Costa-Pereira S, Ingelfinger F, InmunoCovidCba, InViV working group, Pasinovich ME, Castelli JM, Vizzotti C, Schaefer M, Villar-Vesga J, Mundt S, Merten CH, Sethi A, Wertheimer T, Lutz M, Vanoaica D, Sotomayor C, Gruppi A, Münz C, Cardozo D, Barbás G, Lopez L, Carreño P, Castro G, Raboy E, Gallego S, Morón G, Cervi L, Acosta Rodriguez EV, Maletto BA, Maccioni M, Becher B. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity. Nat Immunol. 2023 Jun;24(6):941-954. doi: 10.1038/s41590-023-01499-w. Epub 2023 Apr 24. PMID: 37095378; PMCID: PMC10232362.

  • * Kuroda M, Halfmann PJ, Uraki R, Yamayoshi S, Kim T, Armbrust TA, Spyra S, Dahn R, Babujee L, Kawaoka Y. SARS-CoV-2 virus lacking the envelope and membrane open-reading frames as a vaccine platform. Nat Commun. 2025 May 14;16(1):4453. doi: 10.1038/s41467-025-59533-4. Epub 2025 May 14. PMID: 40360482; PMCID: PMC12075476.

  • * Paris C, Bénézit F, Geslin M, Polard E, Baldeyrou M, Turmel V, Tadié É, Garlantezec R, Tattevin P. COVID-19 vaccine hesitancy among healthcare workers. Infect Dis Now. 2021 Aug;51(5):484-487. doi: 10.1016/j.idnow.2021.04.001. Epub 2021 May 5. PMID: 33964486; PMCID: PMC8098031.

  • * Anjorin AA, Odetokun IA, Abioye AI, Elnadi H, Umoren MV, Damaris BF, Eyedo J, Umar HI, Nyandwi JB, Abdalla MM, Tijani SO, Awiagah KS, Idowu GA, Fabrice SNA, Maisara AMO, Razouqi Y, Mhgoob ZE, Parker S, Asowata OE, Adesanya IO, Obara MA, Jaumdally S, Kitema GF, Okuneye TA, Mbanzulu KM, Daitoni H, Hallie EF, Mosbah R, Fasina FO. Will Africans take COVID-19 vaccination? PLoS One. 2021;16(12):e0260575. doi: 10.1371/journal.pone.0260575. Epub 2021 Dec 1. PMID: 34851998; PMCID: PMC8635331.

  • * Arroyo-Sánchez D, Cabrera-Marante O, Laguna-Goya R, Almendro-Vázquez P, Carretero O, Gil-Etayo FJ, Suàrez-Fernández P, Pérez-Romero P, Rodríguez de Frías E, Serrano A, Allende LM, Pleguezuelo D, Paz-Artal E. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency. J Clin Immunol. 2022 Feb;42(2):240-252. doi: 10.1007/s10875-021-01174-5. Epub 2021 Nov 17. PMID: 34787773; PMCID: PMC8596355.

  • * Brambilla M, Canzano P, Valle PD, Becchetti A, Conti M, Alberti M, Galotta A, Biondi ML, Lonati PA, Veglia F, Bonomi A, Cosentino N, Meroni PL, Zuccotti GV, D'Angelo A, Camera M. Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study. Thromb Res. 2023 Mar;223:24-33. doi: 10.1016/j.thromres.2023.01.015. Epub 2023 Jan 18. PMID: 36702064; PMCID: PMC9846886.

  • * Schneider L, Schubert L, Winkler F, Munda P, Winkler S, Tobudic S. SARS-CoV-2 Vaccine Response in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2022 Sep;20(9):2145-2147.e2. doi: 10.1016/j.cgh.2022.04.006. Epub 2022 Apr 26. PMID: 35487452; PMCID: PMC9040499.

  • * Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, Bestwick J, Bramhall K, Chance R, Evangelou N, George K, Giovannoni G, Godkin A, Grant L, Harding KE, Hibbert A, Ingram G, Jones M, Kang AS, Loveless S, Moat SJ, Robertson NP, Schmierer K, Scurr MJ, Shah SN, Simmons J, Upcott M, Willis M, Jolles S, Dobson R. COVID-19 Vaccine Response in People with Multiple Sclerosis. Ann Neurol. 2022 Jan;91(1):89-100. doi: 10.1002/ana.26251. Epub 2021 Nov 17. PMID: 34687063; PMCID: PMC8652739.

  • * Riedmann U, Chalupka A, Richter L, Werber D, Sprenger M, Willeit P, Rijksen M, Lodron J, Høeg TB, Ioannidis JP, Pilz S. Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: A cohort study. J Infect. 2025 Jun;90(6):106497. doi: 10.1016/j.jinf.2025.106497. Epub 2025 Apr 30. PMID: 40315999.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.